Patients treated with MOC31PE show immunogenic responses
In a new study titled “Immune stimulatory effect of anti-EpCAM immunotoxin – improved overall survival of metastatic colorectal cancer patients”, Acredit member Yvonne Andersson has shown that patients treated with the immunotoxin MOC31PE experiences a longer overall survival than those who did not receive it. Further, Yvonne’s research showed that these patients appeared to experience an immunogenic response from the MOC31PE that caused T-cell activation, which was not present in other cohorts. The work shows that in patients with advanced disease there is a benefit for anti-EpCAM treatment that may be related to a previously unknown immunogenicity caused by MOC31PE.
Read the full article here.